<DOC>
	<DOCNO>NCT03044184</DOCNO>
	<brief_summary>This study aim explore effectiveness tranexamic acid ( also know trans amine TXA ) reduce hematoma expansion patient hemorrhagic stroke give acute phase . METHODOLOGY This Phase III , parallel-group double-blind randomise placebo control trial . Patients allocate control group receive standard care hemorrhagic stroke accord 2015 American Heart Association guideline . Patients allocated intervention group receive , addition standard care , load dose intravenous TXA 1gm within 3 hour symptom onset follow 1gm maintenance dose 8 hour . Timing dose accordance previous establish study protocol . Patients intervention group receive single treatment course TXA . Study subject identify either on-duty clinician Department Neurosurgery institution study investigator . Should patient meet study eligibility criterion consent obtain either patient his/her next kin . 1:1 block randomization perform remote internet randomization service access website . Patients allocate intervention arm 1gm TXA add 100ml normal saline ( 0.9 % ) infuse 10 minute load dose . This follow maintenance dose 1gm TXA 500ml intravenous isotonic solution infuse 120mg/hour ( 60ml/hour ) 8 hour . Patient 's allocate control arm equal volume normal saline ( 0.9 % ) infuse placebo . The patient outcome assessor blind study group allocation . The primary endpoint study assess percentage change brain blood clot volume compute tomography brain scan admission , 6 hour later , 24 hour 1 week .</brief_summary>
	<brief_title>Tranexamic Acid Spontaneous Acute Cerebral Hemorrhage Trial</brief_title>
	<detailed_description>INTRODUCTION There treatment option patient spontaneous intracerebral hemorrhage , type hemorrhagic stroke especially prevalent among Chinese , acute phase . Blood clot expansion brain ( hematoma expansion ; HE ) one significant predictor poor outcome patient . Tranexamic acid ( TXA ) commonly use medication available acute Hospital Authority hospital prescribe variety condition bleed occurs , example epistaxis menorrhagia . Intravenous administration TXA proven benefit severe trauma patient reduce mortality also prevent recurrent rupture brain aneurysm another type hemorrhagic stroke . The medication safe proven improve outcome patient . A previously perform pilot study explore safety feasibility administrate intravenous TXA patient hemorrhagic stroke recently perform conclude medication 's safety . There also trend significance reduce percentage change hematoma volume patient receive TXA . This study aim explore effectiveness TXA reduce hematoma expansion patient hemorrhagic stroke give acute phase . METHODOLOGY This Phase III , parallel-group double-blind randomise placebo control trial . Patients allocate control group receive standard care hemorrhagic stroke accord 2015 American Heart Association guideline . Patients allocated intervention group receive , addition standard care , load dose intravenous TXA 1gm within 3 hour symptom onset follow 1gm maintenance dose 8 hour . Timing dose accordance previous establish study protocol . Patients intervention group receive single treatment course TXA . Study subject identify either on-duty clinician Department Neurosurgery institution study investigator . Should patient meet study eligibility criterion consent obtain either patient his/her next kin . 1:1 block randomization perform remote internet randomization service access website . Patients allocate intervention arm 1gm TXA add 100ml normal saline ( 0.9 % ) infuse 10 minute load dose . This follow maintenance dose 1gm TXA 500ml intravenous isotonic solution infuse 120mh/hour ( 60ml/hour ) 8 hour . Patient 's allocate control arm equal volume isotonic solution infuse placebo . The patient outcome assessor blind study group allocation . The primary endpoint study assess percentage change brain blood clot volume compute tomography brain scan admission , 6 hour later , 24 hour 1 week . Volumetric analysis brain scan perform two radiologist blind patient 's study group allocation.. Secondary endpoint assess research assistant blind patient 's study group allocation . One endpoint functional outcome term Glasgow Outcome Scale modify Rankin scale 3 month 6 month stroke . Another secondary endpoint quality life 3 month 6 month adopt Stroke-specific Quality Life Scale . Other secondary endpoint include death within 30 day admission , vascular occlusive event ( myocardial infarction , pulmonary embolism , deep vein thrombosis ) , ischemic stroke , seizures TXA-associated adverse effect .</detailed_description>
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Cerebral Hemorrhage</mesh_term>
	<mesh_term>Tranexamic Acid</mesh_term>
	<mesh_term>Antifibrinolytic Agents</mesh_term>
	<mesh_term>Tranylcypromine</mesh_term>
	<criteria>1 . Patients CT evidence supratentorial intracerebral hemorrhage 2 . Initiation trial medication within 3 hour time symptom onset . 3 . Ethnic Chinese 4 . Reasonable expectation completion outcome measure followup 5 . Written inform consent either patient nextofkin legal guardian . 1 . Patients expect survive 24 hour admission . 2 . Patients brainstem herniation syndrome admission . 3 . Patients need immediate neurosurgical intervention . 4 . GCS 5 less admission i.e . GCS score 2 accord Hemphil ICH score1 . 5 . Previous antiplatelet anticoagulant medication use . 6 . Known thrombocytopenia coagulopathy . 7 . Disseminated intravascular coagulation admission . 8 . Acute sepsis admission . 9 . Intracerebral hemorrhage ( ICH ) secondary intracranial vascular lesion : aneurysm , arteriovenous malformation , neoplasm dural venous sinus thrombosis . 10 . Previous venous thromboembolic disease : deep venous thrombosis . 11 . History ischemic stroke transient ischemic attack within 12 month . 12 . History ischemic heart disease myocardial infarction . 13 . History peripheral vascular disease . 14 . Patients previous disability ( prestroke modify Rankin scale score &gt; 2 ) 15 . Pregnancy breast feed . 16 . History allergy tranexamic acid</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Tranexamic Acid</keyword>
	<keyword>Antifibrinolytic</keyword>
</DOC>